nobiletin has been researched along with palbociclib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T; Fu, W; Hu, X; Liu, L; Luo, X; Xu, J; Zhang, W; Zhou, T; Zou, Y | 1 |
1 other study(ies) available for nobiletin and palbociclib
| Article | Year |
|---|---|
Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Female; Flavones; G1 Phase Cell Cycle Checkpoints; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Pyridines; S-Phase Kinase-Associated Proteins; Signal Transduction | 2021 |